In a small early clinical trial, single doses of the oral therapy alixorexton were found to be generally well tolerated and to improve wakefulness — both objective and self-reported — in adults with narcolepsy types 1 and 2. “We observed similarly robust wake-promoting effects” with the treatment candidate…
News
Positive, strong emotions may trigger cataplexy, or a sudden loss of muscle tone, in people with narcolepsy by activating a brain pathway dependent on the oxytocin hormone that switches off nerve cells responsible for maintaining muscle tone, a study in mice suggests. Researchers found that reuniting narcoleptic mice with…
The U.S. Food and Drug Administration (FDA) has approved Takeda‘s oral therapy Orzeyful (oveporexton) for adults with narcolepsy type 1 (NT1). “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine…
Looking at patterns of electrical activity in the brain during sleep may help to distinguish between children with narcolepsy and those with other sleep-related disorders, a new study from Australia demonstrates. The researchers noted that “previous studies examining sleep [electrical activity] in patients with narcolepsy and [other conditions] have…
In narcolepsy, targeting specific nerve cells involved in sleep–wake transitions may offer a way to address excessive daytime sleepiness and cataplexy, a sudden loss of muscle tone that happens while a patient remains conscious, according to a study in mice. Targeting these nerve cells could offer “a novel therapeutic…
The U.S. Food and Drug Administration (FDA) has granted fast track designation to Lu AH69593, an experimental oral therapy Lundbeck is developing to treat narcolepsy. The FDA awards this designation to help speed the development of medicines designed to treat serious disorders and fill unmet medical needs. With…
Managing narcolepsy works best when medication is paired with routine sleep habits, healthy lifestyle changes, and personal support systems, with some people controlling symptoms well using little or no medication, a new study shows. The qualitative study from Slovakia highlights how behavioral strategies, psychological coping, and support from family…
Daytime wakefulness and certain patterns of nighttime sleep fragmentation may help distinguish adults with narcolepsy type 1 (NT1) from those with type 2 (NT2), according to an analysis of participants who were not taking narcolepsy medications while enrolled in one of two eight-week clinical trials. People with NT2 showed…
The U.S. Food and Drug Administration (FDA) has agreed to review an application seeking approval of Axsome Therapeutics‘ experimental therapy AXS-12 (reboxetine) to treat cataplexy — a sudden drop in muscle tone — in people with narcolepsy. The company said it expects the FDA to issue a decision…
Long-term treatment with the experimental oral therapy alixorexton safely improved wakefulness, eased fatigue, and boosted cognition for people with narcolepsy in clinical trials, according to interim data announced by alixorexton’s developer, Alkermes. “These long-term results represent a significant contribution to our understanding of alixorexton as a potential new…
Recent Posts
- ‘Potent’ oral therapy found to boost wakefulness in adults with narcolepsy
- When hardship hits home, the narcolepsy community shows up
- Brain hormone may drive sudden loss of muscle tone in narcolepsy
- The invisible battle: Narcolepsy, depression, and finding my worth
- FDA approves first therapy targeting cause of narcolepsy type 1